| pubmed-article:3157587 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3157587 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:3157587 | lifeskim:mentions | umls-concept:C0034798 | lld:lifeskim |
| pubmed-article:3157587 | lifeskim:mentions | umls-concept:C0018546 | lld:lifeskim |
| pubmed-article:3157587 | lifeskim:mentions | umls-concept:C1510827 | lld:lifeskim |
| pubmed-article:3157587 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:3157587 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:3157587 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:3157587 | pubmed:dateCreated | 1985-6-19 | lld:pubmed |
| pubmed-article:3157587 | pubmed:abstractText | Agonist competition for [3H]spiperone binding to striatal dopamine D2 receptors was studied in rats rendered supersensitive by chronic treatment with haloperidol. The classical dopamine agonist (-)-N-n-propylnorapomorphine displaced [3H]spiperone biphasically, with IC50 values of 0.5 and 140 nM for the high and low affinity components, respectively. Neither the relative density nor the affinity of either site for (-)-N-propylnorapomorphine was affected by chronic haloperidol treatment. On the other hand, the novel agonist EMD 23 448 displaced [3H]spiperone monophasically. Although this agent only displays potent dopaminergic agonism in supersensitive animals, chronic treatment with haloperidol likewise did not alter the affinity of this drug for [3H]spiperone binding sites. The results suggest that the enhanced in vivo potency of certain agonists in supersensitive animals is probably not mediated by changes in D2 receptor affinity. | lld:pubmed |
| pubmed-article:3157587 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3157587 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3157587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3157587 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3157587 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:3157587 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:3157587 | pubmed:author | pubmed-author:FriedhoffA... | lld:pubmed |
| pubmed-article:3157587 | pubmed:author | pubmed-author:GoldsteinMM | lld:pubmed |
| pubmed-article:3157587 | pubmed:author | pubmed-author:SchweitzerJ... | lld:pubmed |
| pubmed-article:3157587 | pubmed:author | pubmed-author:MellerEE | lld:pubmed |
| pubmed-article:3157587 | pubmed:author | pubmed-author:BohmakerKK | lld:pubmed |
| pubmed-article:3157587 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3157587 | pubmed:day | 12 | lld:pubmed |
| pubmed-article:3157587 | pubmed:volume | 109 | lld:pubmed |
| pubmed-article:3157587 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3157587 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3157587 | pubmed:pagination | 389-94 | lld:pubmed |
| pubmed-article:3157587 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:meshHeading | pubmed-meshheading:3157587-... | lld:pubmed |
| pubmed-article:3157587 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3157587 | pubmed:articleTitle | Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro. | lld:pubmed |
| pubmed-article:3157587 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3157587 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:3157587 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
